DNA
Ginkgo Bioworks Holdings, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +27.3% ·
share flow +2.7% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +5 | 25.52M | $252.75M | +9 | −4 |
| Q1 2026 | 72 | -1 | 23.15M | $141.95M | +6 | −7 |
| Q4 2025 | 73 | +2 | 24.08M | $200.09M | +2 | — |
| Q3 2025 | 15 | -2 | 16.22M | $236.55M | — | −2 |
| Q2 2025 | 14 | 0 | 15.99M | $179.94M | +2 | −2 |
| Q1 2025 | 11 | -3 | 10.22M | $58.26M | — | −3 |
| Q4 2024 | 14 | +3 | 10.20M | $100.21M | +3 | — |
| Q3 2024 | 10 | -3 | 9.70M | $79.02M | — | −3 |
| Q2 2024 | 13 | — | 419.17M | $140.02M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 3.58M | 0.0% | $35.13M | 0.1% | Held | 3 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 3.36M | 0.0% | $32.97M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 3.36M | 0.0% | $32.97M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 3.36M | 0.0% | $32.97M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Baillie Gifford ✦ | 3.36M | 0.0% | $32.97M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Millennium Management ✦ | 670.07K | +357.4% | $6.58M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 645.36K | -2.1% | $6.34M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 546.42K | -37.4% | $5.37M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 437.02K | +4.9% | $4.29M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 437.02K | +4.9% | $4.29M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | State Street Global Advisors ✦ (passive) | 238.83K | — | $2.35M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Glenview Capital ✦ | 187.50K | -60.5% | $1.84M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 141.74K | New | $1.39M | 0.0% | New | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 114.65K | +65.1% | $1.13M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 99.80K | New | $980,036 | 0.0% | New | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 82.81K | +4.0% | $814,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 82.81K | +4.0% | $814,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Marshall Wace ✦ | 67.68K | New | $664,657 | 0.0% | New | 1 | SEC ↗ |
| 19 | Marshall Wace ✦ | 67.68K | New | $664,657 | 0.0% | New | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 37.61K | -7.0% | $369,359 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 37.61K | -7.0% | $369,359 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 37.61K | -7.0% | $369,359 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $1.39M | 0.0% |
| Point72 Asset Management | $980,036 | 0.0% |
| Marshall Wace | $664,657 | 0.0% |
| Marshall Wace | $664,657 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 140 shares, $0 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 330 sh · $2,302
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology